The global Sepsis Diagnostics Market size is expected to reach USD 1.4 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.6% over the forecast period. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period. Sepsis is a bloodstream disease that occurs as a result of a response to pathogenic microorganisms present in the blood. Patients suffering from this disease experience severe inflammation, which leads to prolonged hospitalization.
According to the WHO, around 30 million people are
estimated to be affected by this disease every year. The NCBI stated that the
largest number of this condition have been observed in the youngest and oldest
age groups. Thus, there is a rising need for the early diagnosis of this
disease. The WHO reported that every year, 1.2 million children and 3 million
newborns are affected by this disease across the world. This has further
boosted the demand for its diagnostic tools for quick results and improved
patient outcomes. Increasing regulatory approval and the introduction of
technologically advanced diagnostic solutions for sepsis are expected to
facilitate market growth over the forecast period.
In May 2018, T2 Biosystems, Inc., a U.S.-based
emerging diagnostic solutions company, received the U.S. FDA approval for its
T2Bacteria Panel, intended for the detection of specific sepsis-causing
bacterial pathogens in human whole blood specimens. The COVID-19 pandemic
affected the growth of diagnostics products for sepsis in a moderately positive
way. The worldwide spread of Coronavirus and the arising instances of sepsis
among COVID-19 patients are probably going to expand the interest for fast
detection, speeding up the use of instruments, reagents, and assay kits for
recognition of sepsis. Pandemic-induced lockdown and other restrictions made
individuals delay going through wellbeing checkups, influencing the number of
tests performed and reagent deals.
The pandemic has featured the risk upon elders, who
are more defenseless to complications, including intense respiratory distress
condition, typically because of pneumonia, which builds the risk of creating
sepsis. This has created a need for the early detection of sepsis among
patients with COVID-19. Symptoms of sepsis, such as multiorgan injuries,
develop in around 2.0 to 5.0% of COVID-19 cases 8 to 10 days
post-hospitalization, based on the estimates of the Global Sepsis Alliance. To
manage this situation, the Biomedical Advanced Research and Development
Authority, in May 2020, extended its partnership with Beckman Coulter for the
development of a digital algorithm to detect sepsis in patients with COVID-19.
Related Press Release@ Sepsis Diagnostics Market Report
Sepsis Diagnostics Market Report
Highlights
- By product, blood culture media held the largest share in 2021 as
it is the most accurate mode of testing for the diagnosis of this disease.
It is also anticipated to witness the fastest CAGR over the forecast
period owing to new product developments in this field
- The microbiology technology segment had the largest share in 2021
and the molecular diagnostics segment is anticipated to exhibit
a lucrative CAGR over the forecast period owing to its high sensitivity,
accuracy, and less turnaround time
- The bacterial pathogen segment held the largest revenue share in
2021 owing to the high prevalence of bacterial sepsis
- The laboratory testing type segment dominated the market in 2021
and accounted for the maximum revenue share on account of the better
accuracy of these tests
- North America dominated the market in 2021 due to a favorable
reimbursement scenario, the presence of established players, and high
awareness about sepsis & its diagnosis
- Middle East Africa is projected to witness a lucrative growth rate
over the forecast period owing to the presence of a large target
population in emerging economies, such as Algeria and Morocco
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment